Zhejiang University — Biomedical Watch V2

Traitements9programmes

Essais4liés

Publications3liées

SourceDBlocale

Traitements

9

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
CD19-BAFF Targeted CAR T-cellsClinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for Autoimmune Diseases.	SEP	Phase 1	Immunomodulation + Thérapie cellulaire	China	À vérifier
CD19/BCMA Targeted CAR T-cellsA Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.	SEP	Phase 1	Thérapie cellulaire + Immunomodulation	China	À vérifier
CD19/BCMA Targeted CAR T-cells and dasatinibA Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.	SEP	Phase 1	Thérapie cellulaire + Immunomodulation	China	À vérifier
durvalumabBackground: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Surgery to remove the tumors is the standard treatment for people diagnosed with early stages of NSCLC. Despite complete removal of these tumors, many recur (happen again). An FDA-approved drug combination to treat early-stage NSCLC prior to the surgery is durvalumab plus standard chemotherapy. The FDA approved infusion drug azacytidine \[AZA\] is used to treat several diseases because it can rapidly kill dividing cells (including cancer cells) but it is not approved for NSCLC. An inhaled (aerosolized) form of AZA is also not approved for NSCLC. However, researchers want to know if an inhaled version of AZA can help improve treatment of people with NSCLC because inhaled AZA goes directly into the lungs with limited absorption into the bloodstream. Objective: To find the safest and most effective dose of inhaled AZA in participants with early-stage non-small cell lung cancer (NSCLC) that can still be removed by surgery. Eligibility: Adults aged 18 and older with operable early-stage NSCLC. Participants will be required to also enroll in NIH protocol 06C0014 which allows for pre- and post-treatment biopsies and bloodwork to be obtained for additional research studies. Design: Participants will be screened. They will have a physical exam with blood tests. Their medical records will be reviewed. They will have imaging scans and tests of their heart and lung functions. Participants will be required to have a tissue sample (biopsy) taken of their tumor prior to receiving study drug and again during surgery after Cycle 3; airway tissue biopsies and collection of collect bronchial (lung) fluid may also be done. Participants will receive the study treatment for 3 cycles. Each cycle is 21 days. They will need to come to the NIH Clinical Center (CC) on days 1-4 of Cycles 1-3. AZA will be given as a drug mist that can be inhaled (like the type of mist in an asthma inhaler) using a nebulizer at the NIH Clinical Center (CC) for 3 days in a row (consecutive days) during the first week of each cycle. The participant will inhale the AZA drug mist for 20 to 30 minutes each time. Participants will also receive durvalumab and a specific 2-drug assigned chemotherapy by intravenous (IV) infusion on day 4 of each cycle. Participants will have a follow-up visit 2 weeks after their last dose of study drugs. Then they will have planned surgery to remove the tumors. Participants will have additional follow-up visits at the NIH CC about 1 and 3 months after the surgery, and then for every 3 months for up to 3 years.	Cancer, Parkinson, SEP	Phase 1	Ablation tumorale non thermique	China	Dispositif/procédure : résultats à interpréter par essai et indication.
Prednisone+TofacitinibThis will be efficacy and safety of Induction and Tapering Therapy with Tofacitinib and Glucocorticoid in patients with Polymyalgia Rheumatica (ITTG PMR): An open-label 52-week randomized controlled trial	Myopathies	Phase 3	À vérifier	China	À vérifier
Regorafenib (BAY 73-4506)A study that aimed to assess the safety and anti-tumor activity of CCAR031 injection in unresectable HCC patients.	SEP	Phase 1	À vérifier	China	À vérifier
Prednisone+TofacitinibThis will be efficacy and safety of Induction and Tapering Therapy with Tofacitinib and Glucocorticoid in patients with Polymyalgia Rheumatica (ITTG PMR): An open-label 52-week randomized controlled trial	Myopathies	Phase 3	À vérifier	China	À vérifier
CD19-BAFF Targeted CAR T-cellsClinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for Autoimmune Diseases.	SEP	Phase 1	Immunomodulation + Thérapie cellulaire	China	À vérifier
CD19/BCMA Targeted CAR T-cells and dasatinibA Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.	SEP	Phase 1	Thérapie cellulaire + Immunomodulation	China	À vérifier

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
CD19/BCMA Targeted CAR T-cells and dasatinib	SEP	Phase 1	NCT04603872	CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies	RECRUITING
CD19-BAFF Targeted CAR T-cells	SEP	Phase 1	NCT06279923	CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases	RECRUITING
C-CAR031	SEP	Phase 1	NCT05155189	A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma	RECRUITING
Prednisone+Tofacitinib	Myopathies	Phase 3	NCT06172361	ITTGPMR — Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica	COMPLETED

Publications

3

Molécule	Indication / population	Titre	Journal	Date
CD19-BAFF Targeted CAR T-cells		CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia.	Leukemia
durvalumab		Data mining methods, tasks, and algorithms for adverse drug reaction analysis in pharmacovigilance: A scoping review.	International journal of medical informatics
durvalumab		Systematic development and optimization of a cIEF method for the charge variants analysis of moderately basic to basic monoclonal antibodies using the Analytical Quality by Design strategy.	Journal of pharmaceutical and biomedical analysis